A 63-year-old woman presented to our hospital with fever and diffuse erythematous rashes on her body. Seventeen days before admission, she was prescribed pregabalin (25 mg/day) and celecoxib (200 mg/day) for her back pain. Laboratory data showed severe hepatic disorder, disseminated intravascular coagulation, and acute renal failure. She improved with multidisciplinary therapy, including steroid pulse therapy, plasma exchange, hemodialysis, and ventilator support. Finally, the disease was diagnosed as drug-induced liver injury caused by pregabalin and celecoxib because pregabalin and celecoxib were positive for DLST in addition to her allergic symptoms, such as fever and rush, and her hepatic function was still normal a year and a half after discontinuing steroid therapy. Pregabalin and Celecoxib-induced liver failure is very rare; however, we must be careful when we use these popular drugs.

A 65-year-old woman with early-onset Alzheimer's disease and type 2 diabetes mellitus received a house call from a medical practitioner. Antiviral therapy could be performed for chronic hepatitis C (genotype 2), and she visited our hospital. It was difficult for her to take tablets because of early-onset Alzheimer's disease; therefore, we provided crushed tablets of sofosbuvir/ledipasvir for 12 weeks. HCV-RNA in her blood showed negative conversion 8 weeks after treatment initiation, and SVR 12 was obtained.

In antiviral therapy against chronic hepatitis C, it is necessary to carefully consider adaptation when treatment is indicated when the patient finds it difficult to take tablets. However, internal treatment with crushed tablets is believed to be an option.

We report a case of antiviral treatment for chronic hepatitis C wherein it was difficult to take a tablet, and we experienced the case of a patient for whom treatment with crushed tablets was successful.

We report the first Japanese patient with unclassified hepatocellular adenoma who presented with acute pain in the abdomen due to intratumoral hemorrhage and whose immunohistological study revealed high tumoral expression of argininosuccinate synthase 1 (ASS1). A 47-year-old woman was referred to our hospital with severe abdominal pain and liver tumors. An abdominal contrast-enhanced computed tomograhy demonstrated multiple hypervascular liver tumors, some of which had hemorrhage and necrosis. Upon tumor biopsy, we found smaller hepatocytes with larger nuclei and the immunohistological study led to the diagnosis of unclassified hepatocellular adenoma. Additional examinations confirmed a high expression of ASS1, a marker for unclassified hepatocellular adenoma. ASS1 expression has been associated with intratumoral bleeding, which is consistent with the clinical course of our patient.